NEW YORK, Sept. 7, 2016 /PRNewswire/ — Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”), a biopharmaceutical company focused on the development of targeted therapeutics for the treatment of inflammatory diseases and cancer, announced today that it has entered into a stock purchase agreement with an existing stockholder for the sale of 4,000,000 shares of the Company’s common…